• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    An object of the present invention is the removal of a compound A from sevoflurane containing fluoromethyl-1,1,3,3,3-pentafluoroisopropenyl ether (compound A) in order to collect sevoflurane from high purity. The present invention relates to a process for the production of sevoflurane containing substantially no compound A, comprising the steps of: contacting a composition containing hydrogen fluoride (HF) and water at a ratio by weight from 1: 1 to 1:30 with a 1st organic liquid containing sevoflurane and compound A, so as to obtain a second organic liquid containing compound A in an amount which is lower than that in the first organic liquid (step 1a) ; and distilling the second organic liquid in the presence of a degradation inhibitor, so as to obtain sevoflurane substantially free of compound A as the main distillation fraction (step 2).
    公开号:BE1024581B1
    申请号:E2017/5207
    申请日:2017-03-29
    公开日:2018-04-11
    发明作者:Takaaki Yoshimura；Toshihiko Oono；Shinya Akiba；Masaki Fujiwara
    申请人:Central Glass Company, Limited；
    IPC主号:
    专利说明:

    DESCRIPTION
    TITLE OF THE INVENTION
    PROCESS FOR PRODUCING SEVOFLURANE
    TECHNICAL FIELD [0001]
    The present invention relates to a process for the production of fluoromethyl ether-l, l, l, 3,3,3-hexafluoroisopropyl (sevoflurane) which has been widely used as a medicament and in particular an anesthetic by inhalation.
    RELATED ART [0002]
    Fluoromethyl ether-l, l, l, 3,3,3-hexafluoroisopropyl (sevoflurane) has been widely used as a safe inhalation anesthetic for use. As described in US Patent No. 4,250,334 (patent literature 1), sevoflurane can be synthesized by adding concentrated sulfuric acid and hydrogen fluoride to paraformaldehyde, heating the reaction mixture obtained, and adding alcohol 1,1,1,3,3,3-hexafluoroisopropyl (HFIP) dropwise to the mixture. A substance of interest (i.e. sevoflurane) can be collected together with an unreacted substance (e.g. HFIP) by collecting a gas generated in the reaction system.
    [0003]
    Different byproducts are generated in the synthesis reaction of sevoflurane above. Among these, a byproduct that is difficult to separate is bis (fluoromethyl) ether. However, it has been described that bis (fluoromethyl) ether can be effectively removed by contacting a reaction mixture of sevoflurane with a Bronstcd acid such as concentrated sulfuric acid, Lewis acid, or a acid immobilized on a resin or the like (patent literature 2: JP patent n ° 2786106). Alternatively, the bis (fluoromethyl) ether can be effectively removed by contacting it with zeolite (patent literature 3: JP patent No. 3240043).
    [0004]
    In addition, it is known that unreacted HFIP can be effectively removed by placing an organic layer containing sevoflurane in contact with a
    BE2017 / 5207 basic aqueous solution of sodium hydroxide or the like (patent literature 4: JP patent No. 4087488).
    [0005]
    Another byproduct in sevoflurane is fluoromethyl ether, 1,1,3,3,3-pentafluoroisopropenyl (usually called compound A). This compound is considered to be a compound that is generated when sevoflurane undergoes a dehydrofluorination reaction. When sevoflurane is contacted with a strong base such as sodium hydroxide, a small amount of this compound may be generated. In addition, it is gradually generated during the distillation and purification of sevoflurane (see the following formula).
    [0006]
    Sevoflurane
    -HF
    Compound A [0007]
    Compound A itself is a stable compound so that it is not easily degraded, even when heated. In addition, it exhibits pseudo-azeotropic behavior in conjunction with sevoflurane. For this reason, once compound A is generated during the purification of sevoflurane, it often becomes difficult to separate compound A from sevoflurane (purification of sevoflurane).
    [0008]
    As a technique for solving such a problem, JP Patent No. 2,786,108 (patent literature 5) describes attempts to distill and purify in the presence of a degradation inhibitor such as sodium hydrogen phosphate. It has been demonstrated that a degradation reaction of sevoflurane to compound A during distillation can be remarkably inhibited by such a technique, and a small amount of compound A is mainly concentrated in a first fraction of distillation so that sevoflurane obtained as the main distillation fraction contains substantially no compound A. Consequently, sevoflurane containing the compound A at a level not higher than the detection limit has been successfully obtained as the main distillation fraction.
    BE2017 / 5207
    LIST OF CITATIONS
    PATENT LITERATURE [0009]
    Patent literature 1: US Patent No. 4,250,334
    Patent literature 2: JP patent n ° 2786106
    Patent literature 3: JP patent n ° 3240043
    Patent literature 4: JP patent n ° 4087488
    Patent literature 5: JP patent n ° 2786108
    SUMMARY OF THE INVENTION
    TECHNICAL PROBLEM [0010]
    The method of patent literature 5 is an excellent method by which the generation of compound A as a by-product after distillation and purification of sevoflurane is inhibited so that a main distillation fraction (sevoflurane fraction) obtained by distillation does not contain compound A. In other words, as described in Examples 2-No. 1, No. 2 of the patent literature 5, when crude sevoflurane containing compound A at 10 to 30 ppm is distilled with the addition of dibasic sodium phosphate as a degradation inhibitor, sevoflurane containing substantially no compound A (which means that compound A is present at less than 1 ppm; this applies below) can be obtained as the main distillation fraction while compound A is mainly concentrated in a first distillation fraction.
    [0011]
    However, the above process is disadvantageous in that loss of sevoflurane is likely to occur. In other words, as indicated above, compound A exhibits pseudo-azeotropic behavior in conjunction with sevoflurane. Consequently, when sevoflurane containing a compound A is distilled according to the patent literature 5, it is inevitable that part of the sevoflurane is distilled in a first distillation fraction together with compound A. More specifically, according to example 2 -n ° 1, n ° 2 of the patent literature 5, the generation of compound A during distillation can be significantly inhibited. Furthermore, the distillation yield (the recovery rate of sevoflurane as the main distillation fraction) remains at a level of 71% to 72%. On the other hand, the amount of the first distillation fraction represents a proportion as high as 10% of the amount recovered from the main distillation fraction. Content
    BE2017 / 5207 sevoflurane in the first distillation fraction reached in Sept 99.6% to 99.8%. Consequently, the first distillation fraction consists mainly of sevoflurane, which leads to a loss of a relatively high amount of sevoflurane for the separation of a small amount of compound A.
    [0012]
    In the situation described above, the present inventors have made attempts to subject a first distillation fraction obtained by the above process directly to precise distillation again so as to isolate sevoflurane. Consequently, however, when the distillation is carried out with the same number of theoretical plates and the same reflux ratio, the compound A constantly detected from the start and practically until the end of the distillation (in other words, the the peak area does not decrease to a level below 1 ppm in the analysis by gas chromatography-FID) (see Comparative example 1). Furthermore, by conducting again a distillation with a number of theoretical plates increased compared to that used for the collection of the first distillation fraction, a first distillation fraction, in which the compound A is concentrated further, could be recovered, which makes it possible to obtain a small amount of sevoflurane containing substantially no compound A as the main distillation fraction. However, such a technique requires the use of a plurality of distillation columns under different conditions, and simply leads to making the operation more complex. Therefore, such a process cannot be considered as a process for effectively obtaining high purity sevoflurane.
    [0013]
    Furthermore, compound A, which is a substance which causes a reduction in the efficiency of distillation, has a structure in which sevoflurane is dehydrofluorinated. Therefore, it was considered that, if HF was allowed to act on compound A, compound A would be converted to sevoflurane with the addition of HF (see the following formulas).
    [0014]
    Compound A + HF (anhydrous) Sevoflurane
    Compound A + HF (anhydrous) + concentrated sulfuric acid - "> Sevoflurane
    BE2017 / 5207 [0015]
    However, even if anhydrous HF is allowed to act on compound A, the above addition reaction does not occur. Even in a system in which concentrated sulfuric acid is added as a reaction accelerator, the reaction does not proceed as expected.
    [0016]
    As described above, a new process by which compound A can be removed from sevoflurane containing compound A so that high purity sevoflurane can be recovered was desirable.
    SOLUTION TO THE PROBLEM [0017]
    Following in-depth studies in order to achieve the above object, the present inventors have observed that, by bringing a compound A into contact with a composition containing hydrogen fluoride (HF) and water at a mass ratio of 1: 1 to 1:30, it is possible to allow the compound A to react gradually so as to be converted into a chemical species (presently called compound X) having an unspecified structure, which can be separated sevoflurane by distillation.
    [0018]
    To date, a specific molecular structure of compound X has not been identified. However, the present inventors have confirmed a phenomenon according to which, when 1,2-dichloroethane (sometimes abbreviated as DCE) is present as an internal standard substance and brought into contact with the above composition, make phase chromatography gaseous of compound A compared to that of DCE decreases over time (see Example 1 below). This undoubtedly suggests that a chemical reaction is induced during the operation, leading to a decrease in the content of compound A. Originally, compound A is not a compound which can be easily degraded when it is heated. In addition, Compound A does not cause the above additional reaction, even when contacted with anhydrous HF. That is, a chemical reaction between compound A and a liquid containing water as the main component occurs at a relatively low temperature around room temperature (this reaction is currently called step 1) . [0019]
    Based on the above observation, the present inventors have contacted sevoflurane containing a small amount of compound A with a composition containing hydrogen fluoride (HF) and water at a ratio of mass
    BE2017 / 5207 from 1: 1 to 1:30. As a result, there is a significant decrease in the amount of compound A compared to the amount of sevoflurane coexisting over time, suggesting that sevoflurane is stable under such conditions, while compound A selectively causes a reaction. chemical (this reaction step is currently called step la).
    [0020]
    Then, the organic layer after the termination of step la is separated from the aqueous layer (of a composition of HF and water), treated by washing with water, and subjected to precise distillation in the presence of 'a degradation inhibitor. Consequently, a sevoflurane containing substantially no compound A (this means that the gas chromatography-FID peak area ratio corresponds to a concentration of less than 1 ppm; this applies below) has been obtained. successfully as a main distillation fraction component in an amount which is remarkably higher than in the case where step 1a (step 2) above is not carried out.
    [0021]
    In addition, a liquid remaining in the form of residues remaining after distillation (or bottom of the tank) obtained following step 2 was analyzed. Unexpectedly, it has been observed that the liquid contains a polyether represented by the following formula:
    R'O (CH 2 O) n R 2 (in which R 1 and R 2 each independently represent hydrogen, a C 1 to C 10 alkyl group, or a haloalkyl group (halogen: fluorine, chlorine, or bromine), n is an integer from 1 to 10, and R 1 and R 2 do not represent hydrogen simultaneously).
    [0024]
    The most typical examples of the polyether chemical species above are polyether 1 and polyether 2 specified below. The residues remaining after distillation (bottom of the tank) after the termination of step 2 tend to contain large amounts of these generated polyethers (see the examples below). (CF3) 2CHO-CH2-O-CH (CF 3 ) 2 <Polyether 1>
    1,1,1,3,3,3-Hexafluoro-2 - [[2,2,2-trifluoro-1 - (trifluoromethyl) ethoxy] methoxy] propane (CF3) 2CHO-CH2-O-CH2-O-CH (CF 3 ) 2 <Polyether 2>
    BE2017 / 5207
    2,2 '- [Oxybis (methylenoxy)] bis [1,1,1,3,3,3-hexafluoropropane] [0026]
    Polyether 3 and polyether 4 can be generated, in addition to or in place of the above polyethers, depending on the distillation time or temperature in step 2. [CF27] (CH 3 ) 2 CHO- (CH 2 -O ) 3 -CH (CF 3 ) 2 <Polyether 3>
    2,2 '- [Oxytris (methylenoxy)] bis [1,1,1,3,3,3-hexafluoropropane] (CF 3 ) 2 CHO- (CH 2 -O) 4-CH (CF 3 ) 2 <Polyether 4>
    2,2 '- [Oxytetra (methylenoxy)] bis [1,1,1,3,3,3-hexafluoropropane] [0028]
    Such a polyether is not a compound that is generated by contacting sevoflurane with a composition containing hydrogen fluoride (HF) and water at a mass ratio of 1: 1 to 1:30. Given this, it is assumed that the polyether is from compound X generated as a result of step 1, and therefore compound X induces some type of chemical reaction during distillation, which leads to the generation of the polyether .
    [0029]
    At present, it is known that polyether (independently of the whole represented by n) can be converted into sevoflurane when it is brought into contact with HF and a reaction accelerator (particularly preferably, concentrated sulfuric acid) ( JP Patent No. 3441735). On the basis of this observation, the present inventors confirmed the generation of sevoflurane at a significant rate by allowing HF and concentrated sulfuric acid to act on the residues (bottom of tank) remaining after step 2 (distillation step) of the present invention. In other words, if necessary, it is possible to convert the bottom residue remaining after step 2 into sevoflurane by letting the residues react with HF and concentrated sulfuric acid (this reaction step is called step 3). It is possible to obtain sevoflurane as the main distillation fraction by distillation of the raw sevoflurane obtained in step 3 (step 4).
    [0030]
    It is possible to reduce a compound A in a mixed composition of sevoflurane and of a compound A so as to collect a sevoflurane containing substantially no compound A by carrying out steps la and step 2 by
    BE2017 / 5207 combination. It is also possible to efficiently use the residues (bottom of tank or bottom of tank) remaining after step 2 by carrying out step 3 and step 4 in combination. Accordingly, an embodiment in which all of steps la, step 2, step 3, and step 4 are combined is a particularly preferable embodiment of the present invention.
    [0031]
    As described above, the present inventors have observed that a compound A can be converted into a compound X under specific conditions (step 1). On the basis of this observation, the present inventors have developed each of steps la to 4 described above. Consequently, the present inventors have succeeded in remarkably suppressing the loss of sevoflurane by elimination of a compound A from sevoflurane by distillation, which is particularly problematic in the method of the patent literature 5. In one more embodiment preferable, it has become possible to convert a compound X contained in bottom residue remaining after step 2, which is an intermediate product of a compound A, in sevoflurane. Accordingly, a method of producing sevoflurane, which has been remarkably improved over conventional methods, may be provided.
    [0032]
    Specifically, the present invention includes the following inventions.
    [Invention 1]
    Method for reducing the amount of a compound A, comprising the following steps:
    step 1 of bringing fluoromethyl ether, 1,3,3,3-pentafluoroisopropenyl (compound A) into contact with a composition containing hydrogen fluoride and water at a mass ratio of 1: 1 to 1:30.
    [Invention 2]
    Process for the production of a second organic liquid, comprising the following step: step la of bringing into contact a liquid (1st organic liquid) containing sevoflurane and fluoromethyl ether-l, l, 3,3,3-pentafluoroisopropenyl (compound A) with a composition containing hydrogen fluoride and water at a mass ratio of 1: 1 to 1:30, so as to obtain the following liquid (i) or (ii) (2nd organic liquid ): (i) an organic liquid containing sevoflurane and compound A in an amount which is less than that in the 1st organic liquid; or (ii) an organic liquid containing sevoflurane and substantially no compound A.
    BE2017 / 5207 [Invention 3]
    Process according to invention 2, in which the temperature during contact is from 0 ° C to 60 ° C.
    [Invention 4]
    Method according to invention 2 or 3, in which the contact is carried out in the presence of hexafluoroisopropyl alcohol (HFIP).
    [Invention 5]
    Process for the production of sevoflurane containing substantially no compound A, comprising the following step:
    step 2 of distillation of the 2nd organic liquid obtained by the process according to any one of claims 2 to 4 in the presence of a degradation inhibitor, so as to obtain sevoflurane containing substantially no compound A as a distillation fraction main.
    [Invention 6]
    Method according to the invention 5, in which the degradation inhibitor used in step 2 is at least one member chosen from the group consisting of NaHCO 3 , Na 2 B 4 O 7 , H3BO4, C 6 H 4 (COOK) (COOH), Na 2 SO 3 , Na 2 HPO 4 , CH 3 COONa, and Na 3 PO 4 . [Invention 7]
    Process according to the invention 5 or 6, further comprising the following stage: stage 3 of bringing anhydrous hydrogen fluoride and a reaction accelerator into contact with the residues (3rd organic liquid) remaining after distillation in l step 2, so as to obtain a liquid (4th organic liquid) in which at least part of a component in the 3rd organic liquid is converted into sevoflurane.
    [Invention 8]
    Method according to invention 7, further comprising the following step:
    step 4 of distillation of the 4th organic liquid so as to obtain sevoflurane containing substantially no compound A as the main distillation fraction.
    BE2017 / 5207 [Invention 9]
    Process according to any one of inventions 2 to 8, in which the 1st organic liquid is obtained as the first distillation fraction in the following stage:
    stage A of distillation of sevoflurane in the presence of a degradation inhibitor so as to collect the first fraction of distillation.
    [Invention 10]
    Process according to the invention 9, in which the degradation inhibitor used in step A is at least one member chosen from the group consisting of NaHCCl ·., Na 2 B 4 O 7 , H3BO4, C 6 H 4 (COOK ) (COOH), Na 2 SO 3 , Na 2 HPO 4 , CH 3 COONa, and Na 3 PO 4 . [Invention 11]
    Process for the production of sevoflurane containing substantially no compound A, comprising the following steps:
    step lb of contacting a liquid (1st organic liquid) containing sevoflurane and fluoromethyl ether-l, l, 3,3,3-pcntafluoroisopropenyliquc (compound A) with a composition containing hydrogen fluoride ( HF) and water at a mass ratio of 1: 1 to 1:30 in the presence of hexafluoroisopropyl alcohol (HFIP) at 0 ° C to 60 ° C, so as to obtain the liquid (i) or (ii ) following (2nd organic liquid): (i) an organic liquid containing sevoflurane and compound A in an amount which is less than that in the 1st organic liquid; or (ii) an organic liquid containing sevoflurane and substantially no compound A; and step 2 of distillation of the 2nd organic liquid in the presence of a degradation inhibitor, so as to obtain sevoflurane containing substantially no compound A as the main distillation fraction.
    [Invention 12]
    Process according to the invention 11, further comprising the following stages: stage 3 of contacting the residues (3rd organic liquid) remaining after distillation in stage 2 with anhydrous hydrogen fluoride and a reaction accelerator, so as to obtain a liquid (4th organic liquid) in which at least part of the 3rd organic liquid is converted into sevoflurane; and
    BE2017 / 5207 step 4 of distillation of the 4th organic liquid in the presence of a degradation inhibitor, so as to obtain sevoflurane containing substantially no compound A as the main distillation fraction.
    ADVANTAGEOUS EFFECTS OF THE INVENTION
    The present invention is advantageous in that a compound A can be converted into a compound X, which can be easily separated from sevoflurane (step 1).
    [0045]
    In addition, in another embodiment, the present invention is advantageous in that it is possible to allow the compound A in a 1st organic liquid to react selectively, so as to produce a 2nd organic liquid containing a reduced content of the compound A or containing substantially no compound A (step la).
    [0046]
    In addition, in another additional embodiment, the present invention is advantageous in that it is possible to produce sevoflurane containing substantially no compound A in a significantly large amount compared to the case where step la n 'is not conducted using, as a raw material, the 1st organic liquid which has been conventionally difficult to use effectively (step la and step 2).
    [0047]
    In addition, in another additional embodiment, the present invention is further advantageous in that it is unexpectedly possible to produce sevoflurane using, as a raw material, residues (bottom of the tank) remaining after distillation in step 2 (step la and steps 2 to 4).
    [0048]
    According to the present invention, it becomes possible to produce sevoflurane by using, as starting material, sevoflurane containing a compound A (1st organic liquid) which has been difficult to use effectively, so as to provide an improved production process. sevoflurane.
    BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1] Figure 1 represents a graph of the relation between the following technical terms currently used: stage A, stage la, stage 2, stage 3, stage 4,
    BE2017 / 5207
    1st organic liquid, 2nd organic liquid, 3rd organic liquid and 4th organic liquid.
    DESCRIPTION OF EMBODIMENTS
    Hereinafter, the present invention is described in detail. The scope of the present invention is not limited to this description. The present invention can be carried out with appropriate changes without departing from the object of the present invention.
    This description includes part or all of the content described in the description and / or drawings of Japanese patent application No. 2017-019555, which is a priority document of the present application. All publications, including prior art documents, patent applications, patent publications and other patent documents cited herein, are presently incorporated by reference in their entirety.
    [0051]
    The technical terms and expressions currently used are defined below.
    Step 1
    Step 1 is a step of bringing fluoromethyl-1,1,3,3,3-pentafluoroisopropenyl ether (called compound A) into contact with a composition containing hydrogen fluoride (HL) and water at a mass ratio of 1: 1 to 1:30 (so as to allow the conversion of compound A into compound X in order to reduce the amount of compound A).
    [0052]
    Stage A
    Step A is a distillation step of sevoflurane in the presence of a degradation inhibitor, so as to collect a first distillation fraction (the first distillation fraction collected in step A is used as the 1st organic liquid in step la in a particularly preferable embodiment of the present invention).
    [0053]
    Step la
    Stage la is a stage of bringing into contact the liquid (1st organic liquid) containing sevoflurane and fluoromethyl ether-l, l, 3,3,3-pentafluoroisopropenyl (hereinafter called compound A)
    BE2017 / 5207 with a composition containing hydrogen fluoride (HF) and water at a mass ratio of 1: 1 to 1:30, so as to obtain a 2nd organic liquid. Specifically, step la can be a step of reacting compound A as a result of contact so as to convert the 1st organic liquid into 2nd organic liquid (step la is particularly characterized in that the 1st organic liquid is used as as reaction material in step 1) (it should be noted that the 2nd organic liquid denotes: (i) an organic liquid containing sevoflurane and the compound A in an amount which is less than that in the 1st organic liquid or ( ii) an organic liquid containing sevoflurane and substantially no compound A; this applies below).
    [0054]
    Step lb
    Step 1b is a step for bringing the first organic liquid containing sevoflurane and fluoromethyl ether-l, l, 3,3,3-pentafluoroisopropenyl (hereinafter called compound A) into contact with a composition containing fluoride. of hydrogen (HF) and water at a mass ratio of 1: 1 to 1:30 in the presence of hexafluoroisopropyl alcohol (HFIP) at 0 ° C to 60 ° C, so as to obtain a 2nd organic liquid . Specifically, step lb can be a step of reacting compound A as a result of contact so as to convert the 1st organic liquid into 2nd organic liquid.
    [0055]
    In addition, step lb is a particularly preferable embodiment of step la. When it is necessary to distinguish step lb from step la with a broader concept, the above step is called step lb however, the description of step la can be applied directly to step lb, unless otherwise noted.
    [0056]
    2nd step
    Stage 2 is a stage of distillation of the 2nd organic liquid obtained in stage la (or stage lb) in the presence of a degradation inhibitor, so as to obtain sevoflurane which contains substantially no compound A as that fraction of distillation.
    [0057]
    Stage 3
    Step 3 is a step of bringing anhydrous HF into contact with a reaction accelerator in contact with residues (or bottom of the tank which is called the 3rd organic liquid) remaining after step 2, so as to obtain a liquid (4th liquid
    BE2017 / 5207 organic) in which at least part of a component in the 3rd organic liquid is converted to sevoflurane.
    [0058]
    Step 4
    Step 4 is a distillation step of the 4th organic liquid in the presence of a degradation inhibitor, so as to obtain sevoflurane containing substantially no compound A as the main distillation fraction. [0059]
    1st organic liquid
    A 1st organic liquid is a liquid composition containing sevoflurane and a compound A.
    [0060]
    2nd organic liquid
    A 2nd organic liquid is a composition obtained by subjecting the 1st organic liquid to step la (or step lb), which is: (i) an organic liquid containing sevoflurane and compound A in an amount which is less than that in the 1st organic liquid or (ii) an organic liquid containing sevoflurane and substantially no compound A.
    [0061]
    3rd organic liquid
    A 3rd organic liquid corresponds to the residues (or bottom of the tank) remaining after distillation in step 2 (it should be noted that this 3rd organic liquid unexpectedly contains a polyether).
    [0062]
    4th organic liquid
    A 4th organic liquid is an organic liquid obtained in step 3, which contains at least sevoflurane.
    [0063]
    Containing substantially no compound A
    The expression containing substantially no compound A means that the concentration of a compound A in a liquid of interest calculated on the basis of the peak area is less than 1 ppm in an analysis by gas chromatography-FID . [0064]
    Below, the above steps are described in detail in rough order of operations.
    BE2017 / 5207 [1] Step 1
    Step 1 is a step of bringing a compound A into contact with a composition containing hydrogen fluoride (HF) and water at a mass ratio of 1: 1 to 1:30. As a result, compound A reacts so that a compound X having an unspecified structure can be obtained (it can be converted into compound X). [0066]
    As described above, a small amount of Compound A can be produced by contacting sevoflurane with a base such as sodium hydroxide. In addition, compound A is gradually generated during the distillation and purification of sevoflurane. An authentic preparation of compound A (compound A having a purity of 99% or more) can be obtained by reaction of sevoflurane with lithium bis (trimethylsilyl) amide serving as Superbase in an anhydrous tetrahydrofuran solvent at -70 ° C at - 60 ° C, followed by distillation and purification (Example 1 described below is an experimental example using this authentic preparation) according to Journal of Fluorine Chemistry, vol. 45 (2), November 1989, P. 239 to P. 253.
    [0067]
    It is possible to carry out step 1 by leaving hydrogen fluoride (HF) and water to act on a compound A (liquid). The order of contacting the three chemical species (compound A, hydrogen fluoride, and water) with each other is not particularly limited. However, it is particularly preferable to mix the hydrogen fluoride and water in advance in order to prepare hydrofluoric acid and then to bring hydrofluoric acid into contact with compound A in order to facilitate handling.
    [0068]
    Currently, the expression composition containing hydrogen fluoride (HF) and water in a mass ratio of 1: 1 to 1:30 means that the composition contains these two chemical species in such a mass ratio. It is also possible that other chemical species (for example, sevoflurane, HFIP or sulfuric acid) are also present.
    [0069]
    The reaction in step 1 does not occur under anhydrous conditions (i.e., when anhydrous hydrogen fluoride is used). Therefore, water must be present in an amount of 1 times by mass or more than that of hydrogen fluoride. In addition, when water is present in an amount greater than
    BE2017 / 5207 times that of hydrogen fluoride by mass, the hydrogen fluoride is excessively diluted, preventing the reaction from occurring to a sufficient degree. In other words, a mass ratio of hydrogen fluoride (HF) and water from 1: 1 to
    1:30 is a step 1 requirement.
    [0070]
    In particular, when the mass ratio of hydrogen fluoride (HF) to water is 1: 1 to 1:10, the reactivity of compound A becomes remarkably high, which is particularly preferable.
    [0071]
    Furthermore, the mass ratio of a compound A and hydrogen fluoride is not particularly limited. When the amount of hydrogen fluoride is too low, this decelerates the reaction rate. When the amount of hydrogen fluoride per 1 g of compound A is 1 g or more, the reaction rate tends to increase, which is preferable. In particular, when the amount of hydrogen fluoride per 1 g of compound A is 4 g or more, the reaction takes place very quickly, which is particularly preferable.
    [0072]
    It should be noted that the reaction in step 1 also starts from the concentration of compound A in a reaction system. As described in step la (which is an embodiment of step 1) below, even if the hydrogen fluoride content is 4 times that of compound A, for example, a reaction solution is formed with a large amount of sevoflurane and a small amount of (e.g. 1000 ppm (0.1% or less)) of compound A, the reaction rate may not increase to a sufficient degree when the concentration of compound A is too weak. In such a case, as described in the examples below, it is preferable that the mass ratio of compound A and HF is 1: 100 or more. In a case where the amount of compound A is clearly low (at the ppm level), the mass ratio can be increased to a high level of, for example, 1:10 3 to 1:10 6 . As indicated above, the mass ratio of compound A and of HF is not necessarily unequivocally determined. It should be noted that even if HF or water is present in an amount which is significantly greater than that of compound A, this does not lead to inhibition of the reaction or the induction of a new side reaction. Consequently, it is desirable that a person skilled in the art can determine and appropriately modify the quantities of HF and of water to be used so as to optimize the conditions which allow compound A to react easily when carrying out this procedure. step.
    BE2017 / 5207 [0073]
    A reaction vessel lined with stainless steel, iron, fluorinated resin, or the like is preferably used as a reactor in step 1. Since hydrogen fluoride is used, a reaction vessel glass is inappropriate. [0074]
    In step 1, it is preferable to carry out a stirring in order to effectively contact a compound A (an organic layer) in contact with an aqueous layer containing water and HF. A specific shaking technique is not limited. A motor-driven rotary agitator can preferably be used on a mass production scale. It is also possible to use a laboratory scale magnetic stirrer. In addition to a method using an agitator, it is possible to use a method in which a reactor itself is agitated or a method in which an organic layer and an aqueous layer are mixed by transfer of a reaction solution ( for example, a reaction solution is passed through a tube). These methods also correspond to the agitation in step 1 of the present invention.
    [0075]
    The reaction temperature in step 1 (temperature during contact above) is not particularly limited; however, it is preferably from 0 ° C to 60 ° C. When it is below 0 ° C, the reaction rate is decelerated. When it is above 60 ° C hydrofluoric acid tends to volatilize, which leads to complicated handling. The reaction temperature in step 1 is more preferably from 15 ° C to 45 ° C and, most preferably, from 25 ° C to 40 ° C. When the reaction temperature is within such a temperature range, the reaction is carried out relatively easily in step 1 and handling is improved.
    [0076]
    It is best to conduct the reaction in step 1 under hermetically sealed conditions. Alternatively, it is possible to conduct the reaction under open conditions when using a system capable of collecting and removing a volatile by-product.
    [0077]
    A reaction product (compound X) in step 1 has not been identified. It could be a chemical species that is difficult to capture by analysis by gas chromatography. It should be noted that, as a result of observation by the present inventors, no solid component (insoluble component)
    BE2017 / 5207 was not generated during this step, and an organic layer generally remains transparent before and after the reaction. Consequently, it is possible to predict the progress of the reaction by bringing into contact a standard substance which is inert to the reaction (for example 1,2-dichloroethane (DCE)) with a compound A so as to determine the ratio of the gas chromatography areas of compound A and DCE. This is a particularly preferable method for understanding the progress of the reaction.
    [0078]
    The time required for step 1 varies depending on the conditions; however, it is typically 10 minutes to 12 hours (720 minutes). It is not necessary to continue the reaction in step 1 to obtain a 100% conversion rate. If it is possible to degrade at least part of the compound A, this would be advantageous for the subsequent collection of sevoflurane in terms of the amount of compound A degraded. Therefore, the conversion rate in the reaction in step 1 is not necessarily determined strictly. In a preferable example, step 1 is completed after a certain amount of time has elapsed (for example, 1 to 5 hours). The reaction time for step 1 can be appropriately determined taking into account the time required to conduct the other steps to produce sevoflurane (the reaction step and the purification step).
    [0079]
    In addition to unreacted compound A, a small amount of a low molecular weight product could be confirmed in the organic layer after the termination of step 1. However, it is generally impossible to detect a polyether which should be present in the residue (bottom of tank) after step 2 described below. In addition, sevoflurane is not significantly generated in this stage and, even if sevoflurane can be detected, the amount of it generally remains at a trace level or lower.
    [2] Step A (distillation in step A)
    Step A is a distillation step of sevoflurane in the presence of a degradation inhibitor so as to collect a first distillation fraction before the step described below.
    [0081]
    The first distillation fraction collected in step A is a liquid composition containing sevoflurane and a compound A. In the present invention, it is preferable to use the first distillation fraction as the 1st
    BE2017 / 5207 organic liquid in stage la taking into account the object of the present invention (distillation in this stage is sometimes called distillation in stage A below so as to distinguish it from the other stages of distillation of the present invention).
    [0082]
    Sevoflurane can preferably be synthesized according to patent literature 1 and purified by the methods described in patent literature 2 to 4. The distillation carried out according to patent literature 5 after the purification process (or before or after purification process) corresponds to distillation in step A.
    [0083]
    It should be noted that the main object of the patent literature 5 and of steps 2 and step 4 described below is to collect a main distillation fraction which corresponds to sevoflurane not substantially containing compound A. Furthermore, the distillation in step A is characterized by the collection of a first distillation fraction which corresponds to sevoflurane containing a compound A.
    [0084]
    A degradation inhibitor which can be used for distillation in step A is an alkali metal hydroxide, hydrogen phosphate, phosphate, hydrogen carbonate, borate or sulfite, an alkali metal salt of acetic acid or phthalic acid, or boric acid as described in the patent literature 5. Examples of an alkali metal hydroxide include NaOH and KOH. The hydrogen phosphate of an alkali metal is a hydrogen phosphate or dihydrogen phosphate of an alkali metal. Specific examples of these include Na 2 HPO4, NaELPCL, K2HPO4, and KH2PO4. Examples of an alkali metal phosphate include a metaphosphate or polyphosphate of an alkali metal as well as an orthophosphate of an alkali metal. Specific examples of these include Na 3 PO4, K3PO4, (NaPO 3 ) 3 , (NaPO 3 ) 4, (KPO 3 ) 3 , and (KPO 3 ) 4. Examples of an alkali metal hydrogen carbonate include NaHCO 3 and KHCO 3 . Examples of an alkali metal borate include diborate, metaborate, tetraborate, pentaborate, hexaborate, and octaborate of an alkali metal. Specific examples of these include NaBO 2 , Na 2 B 4 O7, NaB 5 O 8 , Na 2 B 6 Oio, Na 2 B 8 0i 8 , Na 4 B 2 O5, KBO 2 , Κ 2 Β 4 Ο7, KB 5 O 8 , K 2 B 6 Oio, and K 2 B 8 0i 8 . Examples of an alkali metal sulfite include Na 2 SO 3 and K 2 SO 3 . Additionally, examples of an alkali metal salt of acetic acid include CH 3 COONa and CH 3 COOK.
    BE2017 / 5207 [0085]
    Examples of an alkali metal salt of phthalic acid include alkali metal salts of o-phthalic acid, m-phthalic acid, and p-phthalic acid. Specific examples of these include o-CeH 4 (COOK) (COOH), mC 6 H 4 (COOK) (COOH), pC 6 H 4 (COOK) (COOH), oC 6 H 4 (COONa) (COOH) ), m-CeH 4 (COONa) (COOH), and p-CeH 4 (COONa) (COOH). Among the additives described above, examples of particularly preferable additives having a strong prevention effect on the degradation of sevoflurane include NaHC'Ch, Na 2 B 4 O7, H 3 BO 4 , C 6 H 4 (COOK) ( COOH), Na 2 SO 3 , Na 2 HPO 4 , CH 3 COONa, and Na 3 PO 4 . Among these, H 3 BO 4 , CöH 4 (COOK) (COOH), Na 2 HPO 4 , CH 3 COONa, and the like having more beneficial effects are more preferable additives.
    [0086]
    A degradation inhibitor can be directly added in a solid state. In such a case, the amount to be added is suitably from 0.01% by mass to 10% by mass, preferably from 0.05% by mass to 5% by mass, and more preferably 0.1 % by mass to 1% by mass relative to the quantity of sevoflurane to be treated.
    [0087]
    It is also possible to add a degradation inhibitor in the form of an aqueous solution. In such a case, the concentration thereof is not particularly limited; however, it is suitably 0.01% by mass at a saturation level (saturated solution), preferably from 0.1% by mass to 10% by mass, and more preferably from 1% by mass to 5% by mass. In addition, the amount of a degradation inhibitor added in the form of an aqueous solution is not particularly limited, and therefore, an appropriate amount to be added can be selected depending on the concentration of the aqueous solution. For example, when the concentration of the aqueous solution is defined at 1% by mass, the amount is suitably from 1% by mass to 200% by mass, preferably from 3% by mass to 100% by mass, and more preferably from 5% by mass to 50% by mass relative to the sevoflurane to be treated.
    [0088]
    Sevoflurane, which is a raw material for distillation in stage A, may contain impurities or a compound A (it should be noted that the use of purified sevoflurane which does not contain substantially no compound A is not particularly limited). In addition, in the case of distillation in the presence of any degradation inhibitor described above, a small amount of compound A
    BE2017 / 5207 can be generated in a tank. When the distillation is carried out under such conditions, a compound A as a whole is collected as the first distillation fraction, which makes it possible to substantially avoid the incorporation of the compound A in a main distillation fraction. However, as indicated above, it is impossible to prevent sevoflurane from being present in the first distillation fraction, even by such a distillation operation in which a degradation inhibitor is present.
    [0089]
    A distillation column used for distillation in step A is not particularly limited. Preferably, however, a distillation column filled with a structured filling material or an unstructured filling material can be used. Examples of structured filling material include Sulzer filling material, Mellapack, Techno-pack and Flexi-pack. Examples of unstructured filling material include Heli-pack, Raschig ring, and Dixon filling material.
    [0090]
    The number of theoretical plates for distillation in stage A is not particularly limited; however, it can be from 2 to 50. In particular, it is preferably from 3 to 30 and more preferably from 5 to 20.
    [0091]
    The reflux ratio is generally from 0.5 to 50, preferably from 1 to 30, and more preferably from 1 to 20.
    [0092]
    The pressure applied during distillation in step A is not particularly limited. It is easy is better to conduct the distillation at ordinary pressure. In such a case, since a main component to be distilled is sevoflurane, the distillation temperature (column top temperature) when collecting a main distillation fraction is the boiling point of sevoflurane, which is from 58 ° C to 59 ° C. The process of distilling components with lower boiling points before collecting a main distillation fraction corresponds to collecting a first distillation fraction. As noted above, there is substantially no difference in boiling point between a compound A and sevoflurane. In fact, the first distillation fraction consists mainly of sevoflurane. Consequently, it is difficult to define a limit point between the temperature for the collection of a first distillation fraction and the temperature for the collection of a main distillation fraction. In
    BE2017 / 5207 Consequently, it is preferable to determine by continuous gas chromatography the composition of each fraction during distillation in an appropriate manner and to continuously collect a first distillation fraction while a compound A is detected and then , to collect a main distillation fraction when it is confirmed that the compound A is substantially undetectable (less than 1 ppm).
    [0093]
    In a preferable embodiment of the present invention, the first distillation fraction is used as the starting material (1st organic liquid) in the subsequent step.
    [3] Step 1
    Step la is a particularly preferable embodiment of step 1 described above. In other words, step la is in common with step 1 in terms of mixing a compound A with HF and water to drive a reaction. Furthermore, step la is characterized in that a compound A serving as raw material is produced in the form of a liquid mixture of sevoflurane and a compound A (1st organic liquid).
    [0095]
    The process for producing a first organic liquid serving as raw material is not particularly limited; however, it is preferable to use a collected liquid as the first distillation fraction during the distillation in step A described above.
    [0096]
    In addition, the 1st organic liquid is converted into a 2nd organic liquid in step la. As indicated above, the 2nd organic liquid designates: (i) an organic liquid containing sevoflurane and a compound A in an amount which is less than that in the 1st organic liquid or (ii) an organic liquid containing sevoflurane and substantially no compound A. A difference between (i) and (ii) is the fact that the conversion of a compound A into compound X is complete. [0097]
    The content of a compound A used as a raw material in the 1st organic liquid in this step is not particularly limited. When the 1st organic liquid is produced by stage A, the content of a compound A in the 1st organic liquid depends on the content of a compound A in the raw sevoflurane before stage A, and it can vary according to the conditions for carrying out the distillation.
    BE2017 / 5207
    The content of a compound A in the 1st organic liquid is generally from 5 ppm to 10,000 ppm and typically from 10 to 1,000 ppm. However, even when the content of a compound A is higher or lower than the above range, it is possible to carry out step la. As a consequence of a decrease in the content of a compound A, the advantages of the present invention are obtained to a sufficient degree.
    [0098]
    As described above, a degradation reaction of the sevoflurane present is not induced under the conditions of step la. In step la, sevoflurane, which is the component, remains as is. Furthermore, a compound A is chemically modified over time so that the compound A is converted into a compound X which can be easily separated from sevoflurane. When step 1a is carried out, sevoflurane acts as an internal standard substance. Therefore, there is no need to add a standard substance such as DCE. After the start of the reaction, it is possible to know the progress of the reaction by sequential determination of the ratio of gas chromatography areas of sevoflurane and of compound A.
    [0099]
    The difference between Stage 1 and Stage 1 described above is simply the fact that sevoflurane which is inert to the reaction is or is not present as an essential component. For this purpose, the conditions described for step 1 can again be applied as conditions for the mass ratio of HF and water, mass ratio of compound A and HE, reactor material, stirring process , reaction temperature, and the like.
    [0100]
    As described above, since the main component in the 1st organic liquid serving as raw material is sevoflurane in the case of step la, the absolute amount of a compound A is generally very low. Therefore, in the case of step la, the mass ratio of compound A: HF tends to be very high, while compound A is generally diluted with a large amount of sevoflurane. In such a case, as described in the section of step 1 above, it is preferable to adjust the mass ratio so that the amount of HF is much greater than that of compound A in many cases. In addition, the reaction rate in step la is also influenced by the mass ratio of HF and water, the stirring process, and the reaction temperature. Therefore, in order to know the progress of the reaction, it is desirable that the ratio of gas chromatography areas of sevoflurane and of compound A can
    BE2017 / 5207 be determined sequentially, which is better than adjusting the primary conditions.
    [0101]
    It should be noted that the objective of step 1a according to the present invention is to reduce the content of a compound A contained in the 1st organic liquid, which does not necessarily mean that the content must be reduced to zero. In other words, in a case where a certain amount (content) of compound A can be reduced in the 1st organic liquid in step la, even if a distillation is carried out in step 2 (described below ) at the same number of theoretical plates and at the same reflux ratio as in the preceding step A, the amount of a first distillation fraction decreases in response to a decrease in the amount of compound A, so as to allow the collection of sevoflurane containing substantially no compound A as the main distillation fraction. The reaction in the step requires a very long time for the reaction to be complete depending on the conditions, which could be relatively insufficient. Therefore, there is a particularly reasonable option to predetermine the time required for step la, conduct a reaction with the predetermined mass ratios, stirring process and reaction temperature, and then complete the reaction step (even if the conversion rate does not reach 100%) within the predetermined time.
    [0102]
    For example, step la is preferably carried out for 30 minutes to 5 hours and more preferably 30 minutes to 2 hours and then completed in a preferable embodiment.
    [0103]
    In addition, since the reaction in step la is a non-uniform liquid-liquid reaction, the presence of a surfactant could promote the reaction. In particular, when hexafluoroisopropyl alcohol (HFIP), which is an amphipathic substance considered to be a surfactant, is present, the rate of decrease in the content of a compound A tends to increase, even if the other conditions are identical (see example 3).
    [0104]
    HFIP is a raw material used for the synthesis of sevoflurane in the patent literature 1 and, therefore, it is often present in a reaction solution for the synthesis of sevoflurane. In addition, HFIP itself does not degrade sevoflurane. Therefore, when conducting step la, it is particularly preferable that HFIP is present. When HFIP is used, the amount
    BE2017 / 5207 thereof is preferably from 0.001 g to 20 g and more preferably from 0.01 g to 10 g per 1 g of sevoflurane in the 1st organic liquid.
    [0105]
    In a particularly preferable embodiment, HFIP is present and a reaction (the contact described above) is carried out at 0 ° C to 60 ° C in step la of the present invention. When the reaction is carried out under such conditions, this tends to lead to an acceleration of the degradation of, in particular, a compound A into compound X. The stage carrying out under such conditions is sometimes referred to herein as step 1b as described above.
    [0106]
    Step 1a can be carried out in the presence of sulfuric acid. Since sulfuric acid is also a raw material used for the synthesis of sevoflurane by the process described in the patent literature 1, it is often present in a reaction solution after termination of the reaction. The present inventors have observed that, when step la of the present invention is carried out, the presence of sulfuric acid does not particularly inhibit the reaction, and there is no sign that a by-product which is difficult to separate from sevoflurane is generated. However, if the amount of sulfuric acid (H2SO4) is extremely high, it could cause inactivation of the water necessary for step la. Therefore, it is not preferable for the mass of sulfuric acid to be much greater than the mass of water, for example. Generally, sulfuric acid in such an extremely high amount is not introduced into a reaction system. However, in a case in which the amount of sulfuric acid is high for certain reasons, it is preferable that the water is present in a mass which is at least equal and, preferably, 2 or more times that of the acid sulfuric.
    [0107]
    After the termination of step la, a separation of two layers can be carried out according to an ordinary method so that an organic layer can be collected. The organic layer thus collected is a 2nd organic liquid. The 2nd organic liquid contains sevoflurane as the main component, as in the case of the 1st organic liquid used as raw material; however, the content of compound A in the 2nd organic liquid is significantly lower than that in the 1st organic liquid. It should be noted that, since the organic layer generally comprises HL used in step la, it is preferable to carry out a purification operation such as washing with an alkaline aqueous solution or washing with water to the organic layer collected in order to decrease
    BE2017 / 5207 a load for a system used in step 2 (distillation) consecutive. Specifically, it is desirable to perform a wash with an alkaline aqueous solution or a wash with water at least once.
    [0108] [4] Step 2 (distillation in step 2)
    Stage 2 is a stage of distillation of the 2nd organic liquid obtained in stage la (or stage lb which is a particularly preferable embodiment of stage 1) in the presence of a degradation inhibitor so as to obtain, as the main distillation fraction, sevoflurane containing substantially no compound A. In order to distinguish distillation in this step from distillation in step A described above, distillation in this step is sometimes referred to as distillation in step 2. It should be noted that the material obtained by distillation in step A is a first distillation fraction while the material obtained by distillation in step 2 is a main distillation fraction.
    [0109]
    As described in detail above, as a result of the reaction of step la, the content of compound A in the 2nd organic liquid is significantly lower than that in the 1st organic liquid. Therefore, it is also possible to collect, as the main distillation fraction, sevoflurane containing substantially no compound A by distillation of the 2nd organic liquid in step 2 under, for example, the same distillation conditions in step A (in terms of number of theoretical plates, reflux ratio, or the like).
    [0110]
    Since the distillation in step 2 is in common with the distillation in step A in terms of the distillation of sevoflurane, the conditions described in detail in the distillation section in step A can be applied again as distillation conditions in step 2 (type or quantity of a degradation inhibitor, a distiller, the number of theoretical plates, the reflux ratio, the distillation pressure and the temperature). It should be noted that the distillation in step 2 is different from the distillation in step A in the description of step 2 is not a first distillation fraction but a main distillation fraction. In other words, a first distillation fraction can be collected while component A is detected as
    BE2017 / 5207 fraction during distillation, and when compound A becomes incollectable, a main distillation fraction can be collected.
    [YES]
    When conducting the distillation in step A before the distillation in step 2, it is common to conduct the distillation in step 2 under the same conditions as the distillation in step A, which is particularly rational. This is due to the fact that the two steps have in common the fact that sevoflurane is distilled so that sevoflurane is obtained as the main distillation fraction. In other words, the objective of distillation in step 2 is to recover sevoflurane to a possible degree as the main distillation fraction from the first distillation fraction under conditions which have already been optimized in stage A. Consequently, it is not necessary to significantly increase the number of theoretical plates or the like instead of optimizing the conditions of the distillation in stage A so as to conduct the distillation in a way tighter for a longer time. It should be noted that, if necessary, the distillation in step 2 can be carried out under more stringent conditions.
    [0112]
    On the other hand, in a case in which the distillation is carried out under distillation conditions which are less strict than those of distillation in stage A (which means that the number of theoretical plates or the reflux ratio is reduced ), it may not be possible to collect a main distillation fraction (sevoflurane containing substantially no compound A) even while conducting the distillation in step 2, although this depends on the degree of reduction of compound A in step la . In a case where the main distillation fraction cannot be collected by conducting the distillation in step 2 under such less stringent conditions, the reduction of compound A through the reaction in step la becomes insignificant , which is not preferable. Furthermore, in a case in which there is a sharp reduction in compound A as a consequence of step la, distillation would be possible, even by making the distillation conditions of the distillation in step 2 less stringent than those of distillation in step A. In such a case, this is advantageous in that the distillation in step 2 can be carried out more easily. In other words, optimal distillation conditions in step 2 are also determined according to the conditions of the previous step. Therefore, it is preferable to adjust the conditions based on the knowledge of a person skilled in the art by checking the degree of collection of sevoflurane as the main distillation fraction.
    BE2017 / 5207 [0113]
    As stated above, although there is no particular limitation of the distillation conditions in step 2, it is possible to save labor in the distillation step and to effectively use a distillation system by conducting the distillation in step 2 under the same conditions (for example, using the same distillation column) of the distillation in step A previously carried out, which may be a preferable embodiment.
    [0114]
    Sevoflurane recovered as the main distillation fraction in the distillation in step 2 can be added to a sevoflurane product. Specifically, the main distillation fraction thus recovered is sevoflurane which could not be collected in step A, which means that sevoflurane can be recovered by step 2 following the previous step.
    [0115]
    A first distillation fraction is also collected during the distillation in step 2. The first distillation fraction is a sevoflurane containing a compound A at a significant rate, as in the case of the first distillation fraction in step A (even if the 2nd organic liquid used as raw material for distillation in step 2 does not contain compound A, a very small amount of compound A can be generated by distillation). This first distillation fraction can be rejected because its quantity is relatively small. Alternatively, it can be collected in order to be reused as a raw material in step la (1st organic liquid).
    [0116]
    Furthermore, the residues (bottom of tank) remaining after the collection of a main distillation fraction during the distillation in step 2 is currently called 3rd organic liquid. This 3rd organic liquid can be rejected. The present inventors have however observed that the 3rd organic liquid contains polyether which may be a raw material of sevoflurane. Therefore, if necessary, step 3 described below can be carried out using the 3rd organic liquid as a raw material.
    [0117]
    As indicated above, typical examples of polyether presently used are polyether 1 and polyether 2. Generally, these polyethers are generated in large quantities. When the time or temperature for distillation in
    BE2017 / 5207 step 2 is extended or increased, polyether 3 and polyether 4 tend to be generated, in addition to or in place of these polyethers.
    [0118] [5] Step 3
    Step 3 is a step of contacting the 3rd organic liquid obtained as the bottom of the tank after step 2 in contact with anhydrous HF and a reaction accelerator (particularly preferably sulfuric anhydride), so as to obtain a 4th organic liquid in which at least part of the polyether in the 3rd organic liquid is converted to sevoflurane.
    [0119]
    As indicated above, there are different types of polyether in the 3rd organic liquid after the end of the distillation in step 2. Generally, the 3rd organic liquid is in the form of a mixed composition of different types of polyethers. However, regardless of the abundance of specific polyether chemical species, the polyethers can be converted to sevoflurane by contacting the 3rd organic liquid with anhydrous HF and a reaction accelerator according to the description of JP Patent No. 3441735. In the in most cases, the quantity of the 3rd organic liquid collected is less than that of the 1st organic liquid serving as raw material in stage la. Therefore, it is also possible to carry out step 3 after carrying out steps 1 and 2 for a plurality of batches so as to obtain a certain amount of recovery of the 3rd organic liquid.
    [0120]
    Examples of the reaction accelerator include: Bronstcd acids such as fuming sulfuric acid, concentrated sulfuric acid, sulfuric acid, fluorosulfuric acid, anhydrous phosphoric acid, phosphoric acid and l 'trifluoromethanesulfonic acid; and Lewis acids such as titanium tetrachloride, aluminum chloride, antimony pentachloride, aluminum trifluoride, sulfuric anhydride, and antimony pentafluoride. Among these, fümant sulfuric acid, concentrated sulfuric acid, sulfuric acid (80% by weight or more), fluorosulfuric acid, phosphoric acid or a mixture thereof is preferable. Particularly preferable is concentrated sulfuric acid. [0121]
    The reaction temperature is not particularly limited; however, it is from 10 ° C to 100 ° C and preferably from 35 ° C to 80 ° C. The sevoflurane generated can be distilled with an unreacted raw material outside of a
    BE2017 / 5207 reaction in the above temperature range, which is preferable. When the reaction temperature is below 10 ° C, the reaction is decelerated, which is not practical, and when it is above 100 ° C, the reaction is excessively accelerated, which makes it difficult to control the reaction, which is not preferable.
    [0122]
    Since the reaction pressure does not significantly influence the reaction, it is not particularly limited. Generally, the reaction can be carried out at 0.1 to 1 MPa.
    [0123]
    The reaction of step 3 can also be carried out in the presence of formaldehyde or paraformaldehyde.
    [0124]
    The mixing ratio of the reaction reagents used in the process of the present invention is specified as follows: a: when formaldehyde is used, the molar number of formaldehyde is added to the total molar number of an oxymethylene group of the polyether in the 3rd organic liquid b: when HLIP is used in combination, the molar number of HLIP is added to the molar number of a hexafluoroisopropenyl group of the polyether in the 3rd organic liquid c: molar number of HP; d: molar number of a reaction accelerator.
    [0125]
    The value of b / a is generally 0.5 to 5 and preferably 0.7 to 3.
    [0126]
    The value of c / a is generally from 1 to 50 and preferably from 3 to 30 (it is preferable that HP is present at least at an equimolar level with respect to an oxymethylene group in order to improve the reaction yield) .
    [0127]
    Currently, d represents the molar number of an arbitrary component. When an arbitrary component is used, the value of d / a is generally 0.5 to 20 times in moles and preferably 0.7 to 5.0 times in moles.
    [0128]
    Preferably, water is not present in step 3. It is not necessary to strictly control the humidity concentration by means of a Karl Pischer water titration apparatus; however, it is not preferable to actively add water to the reaction system as in step 1 or step la. The amount of water is desirably 0.01 mol or less when the above a is 1 mol. In addition, when fümant sulfuric acid, sulfuric anhydride, or the like is
    BE2017 / 5207 used as a reaction accelerator, even if a very small amount of water is present in the reaction system, such a reaction accelerator captures (inactive) water, which leads to substantially anhydrous conditions , which is preferable.
    In addition, as in step 1 or step la, the reaction in step 3 occurs effectively during agitation, which is preferable.
    [0129]
    An embodiment of the reaction in step 3 is not particularly limited. The reaction is carried out under hermetically sealed conditions or under open conditions, so that a 4th organic liquid in which at least part of the polyether in the 3rd organic liquid is converted into sevoflurane can be obtained over time.
    [0130]
    When the reaction is carried out under open conditions, a sevoflurane product has a boiling point of 58 ° C to 59 ° C, at which the reaction in step 3 can occur to a sufficient degree. Therefore, a technique of mixing the 3rd organic liquid, hydrogen fluoride, the reaction accelerator as mentioned above (particularly preferably, concentrated sulfuric acid) and, if necessary, paraformaldehyde in certain quantities and gradual increase in temperature to bring a reaction around 60 ° C is preferable. Once sevoflurane is generated, sevoflurane quickly becomes a vapor at such a temperature. By capturing such vapor using a water-cooled trap or the like, it is possible to collect the generated sevoflurane. The sevoflurane collected by such a process is a crude sevoflurane and therefore may contain HF or a polyether as the reaction material; however, high boiling components can be eliminated. Consequently, it is preferable to collect the raw sevoflurane by such a technique (the raw sevoflurane obtained by vapor collection in the manner described above is within the scope of the 4th organic liquid).
    [0131]
    Since the 4th organic liquid obtained above generally comprises HF used as a raw material, it is preferable to carry out a purification operation such as washing with an alkaline aqueous solution or washing with water for the organic layer collected in order to reduce a load for a system used in step 4 (distillation) consecutive. Specifically, it is desirable to perform a wash with an alkaline aqueous solution or a wash with water at least once.
    BE2017 / 5207 [0132] [6] Step 4 (distillation in step 4)
    Step 4 (distillation in step 4) is a step of obtaining sevoflurane containing substantially no compound A as the main distillation fraction by distillation of the 4th organic liquid obtained in step 3 in the presence of a degradation inhibitor.
    [0133]
    This step can be carried out in the same way as step 2, except that the quantity of a subject to be distilled is less than that in step 2 (distillation in step 2). The type or amount of a degradation inhibitor, the number of theoretical distillation trays, a method for switching from collecting a first distillation fraction to collecting a main distillation fraction, and other conditions described in step 2 can be applied again in this step.
    [0134]
    The quantity of the 4th organic liquid collected is less than that of the 2nd organic liquid serving as raw material in stage 2. Consequently, it is also possible to carry out stage 4 after carrying out stages 1 and 2 for a plurality of batches to obtain a certain amount of recovery of the 4th organic liquid. However, in this step, insofar as it is possible to distill the 4th organic liquid in order to collect the sevoflurane of high purity (sevoflurane not containing substantially no compound A), a specific process of the operation is not limited.
    [0135]
    EXAMPLES
    The present invention is described in more detail below with reference to the following examples. However, the present invention is not limited to these.
    [Example 1] [0136] (Step 1)
    Compound A (purity: 99% or more) (5 g), HF (20 g), water (100 g), and 1,2-dichloroethane (DCE) serving as internal standard substance (15 g) are mixed, followed by stirring in an airtight polytetrafluoroethylene resin container for 5 hours at 20 ° C to 25 ° C, so as to conduct a reaction. During the reaction, the peak area ratio of [compound A] / [DCE] is determined by analysis by
    BE2017 / 5207 gas chromatography-FID at 1 hour intervals. It should be noted that a liquid sample is placed in contact with NaF for dehydrofluorination and then analyzed by gas chromatography (the retention time for compound A is approximately 5.2 minutes and the retention time for DCE is approximately 16.5 minutes under gas chromatography conditions).
    [0137]
    Consequently, while the peak area ratio of [compound A] / [DCE] is 0.57 immediately before the start of the reaction, it becomes 0.48, 0.38, 0.31, 0.25, and 0.19 at 1, 2, 3, 4 and 5 hours, respectively, after the start of the reaction. In other words, after the 5 hour delay, the peak area ratio decreases to a third of the initial level. No specific main peak is detected as a product peak; however, it is confirmed that compound A is chemically modified in step 1. [0138]
    In addition, sevoflurane is not significantly detected in the reaction mixture. It is observed that the above operation does not substantially convert the compound A into sevoflurane.
    [Example 2] [0139] (Step A)
    The standard substance of compound A (used in Example 1) is used so that sevoflurane containing compound A at 100 ppm is prepared. The sevoflurane obtained (1000 g) is introduced into a glass distillation tank. In addition, a 1% aqueous sodium hydrogen phosphate solution (70 g) is added thereto, followed by distillation at ordinary pressure using a distillation column with 10 theoretical plates at a reflux ratio of 5 to 20.
    [0140]
    The distillate is analyzed by gas phase chromatography-FID and collected as the first distillation fraction while compound A is detectable at 1 ppm or more. Then, when compound A is detected at a level below 1 ppm, the distillate is collected in the form of a main distillation fraction.
    [0141]
    Consequently, the amount recovered from the first distillation fraction is 267 g, in which the content of compound A is 341 ppm. Furthermore, the amount recovered from the main distillation fraction is 720 g, in which the compound A is not detected (less than 1 ppm) (collection yield of the main distillation fraction = 72%).
    BE2017 / 5207 [0142] (Stage la)
    The first distillation fraction (content of compound A: 341 ppm) obtained above (step A) (240 g) is introduced into a stainless steel autoclave, and an aqueous solution of HF (prepared by dissolving 10 g of HF anhydrous in 50 g of water) is added. The autoclave is closed and then stirred using a stirrer (reaction temperature = 20 ° C to 25 ° C).
    [0143]
    The reaction is terminated 5 hours after the start of the reaction. The organic layer inside the autoclave is recovered and washed with water. Then, the organic layer is analyzed by gas chromatography. Consequently, the content of compound A is 123 ppm. In other words, the content of compound A decreases significantly after the 5 hour period (conversion rate: 63%). The entire amount of the residual organic layer is washed with an aqueous solution of sodium hydroxide so that the acids are removed.
    [0144] (Step 2)
    The total amount of the organic layer (after washing) obtained above (step la) is introduced into a stainless steel distiller, 17 g of an aqueous 1% sodium hydrogen phosphate solution are added thereto, followed by distillation at ordinary pressure by means of a distillation column with 10 theoretical plates at a reflux ratio of 5 to 20.
    [0145]
    The distillate is analyzed by gas phase chromatography-FID and collected as the first distillation fraction in which compound A is detectable at 1 ppm or more. Then, once it is confirmed that Compound A is less than 1 ppm, the distillate is collected as a main distillation fraction. [0146]
    Consequently, 76 g of the first distillation fraction are recovered, in which the content of compound A is 330 ppm. In addition, 128 g of the main distillation fraction are recovered, in which the compound A is not detected (less than 1 ppm). As described in Comparative Example 1 below, it is observed that it is impossible to obtain the main distillation fraction by simply distilling the first distillation fraction obtained above (step A). Furthermore, in this step (step 2), the main distillation fraction (in an amount which is not high but at a significant level) is successfully recovered. That is
    BE2017 / 5207 probably due to the fact that the content of compound A could have been reduced in the above step (step la).
    [0147]
    In addition, 31 g of tank bottom (it should be noted that all of the components having boiling points higher than the boiling point of the main distillation fraction are considered to be the tank bottom). The bottom of the tank is analyzed by gas chromatography-FID. As a result, polyether 1, polyether 2, polyether 3, and sevoflurane are detected at 42%, 6%, 1%, and 20%, respectively (while no compound A is detected). In addition, the detected sevoflurane is considered to be a sevoflurane which has not been distilled but remained in the tank during distillation, other than sevoflurane which was generated by the reaction during distillation.
    [0148] (Steps 3 and 4)
    The bottom of the tank (31 g) obtained in step 2 is introduced into a stainless steel autoclave, and 98% sulfuric acid (100 g) and hydrogen fluoride (200 g) are added to that -this. The mixture is gradually heated for 4 hours at 65 ° C.
    [0149]
    The vapor generated during the reaction is captured using a water trap, and the organic layer obtained is washed with water. The organic matter (26 g) is recovered.
    [0150]
    The organic matter obtained is analyzed by gas chromatography-FID. It is observed that this organic material contains 96.3% sevoflurane.
    [0151]
    The organic material is washed with aqueous sodium hydroxide, then subjected to distillation under the conditions described in step 2. Consequently, 14 g of sevoflurane (purity: 99.9% or more) are obtained.
    [0152]
    As described above, by carrying out steps 3 and 4 in combination, it is possible to recover more sevoflurane of high purity, which it was impossible to collect by conventional techniques.
    BE2017 / 5207 [Example 3] [0153] (Step lb)
    In example 3 and the following examples, a reaction corresponding to step lb is carried out on a small scale (one tenth of the scale of example 2) as a model test similar to step la of Example 2 (using a small stainless steel reactor which can be hermetically sealed).
    [0154]
    First, the standard substances of compound A and sevoflurane are mixed so that sevoflurane containing compound A at 340 ppm is prepared. Sevoflurane is called reaction material in Example 3 and the following examples.
    [0155]
    An aqueous solution of HF (prepared by dissolving 1.0 g of anhydrous HF in 5.0 g of water) is added to 24 g of sevoflurane containing compound A at 340 ppm. In addition, 1.0 g of HFIP is added and an autoclave is closed. Agitation is initiated using a magnetic stirrer and the interior temperature is maintained at 20 ° C to 25 ° C.
    [0156]
    After a period of 5 hours, gas chromatography-FID is carried out for determination. The conversion rate of compound A is estimated to be 73%. Since HFIP is added, the conversion rate is slightly improved from 63% to 73%, compared to Example 2.
    [Example 4] [0157]
    A reaction corresponding to step lb is carried out by additional addition of 1.0 g of concentrated sulfuric acid under the conditions described in step lb of Example 3.
    [0158]
    After a period of 5 hours, gas chromatography-FID is carried out for determination. The conversion rate of compound A is estimated to be 71%. In other words, the results of Example 4 are not significantly different from those of Example 3. It is observed that the reaction would not be inhibited, even in the presence of sulfuric acid.
    BE2017 / 5207 [Example 5] [0159]
    A reaction corresponding to step lb is carried out under the conditions described in step lb of Example 4 at a reaction temperature of 45 ° C.
    [0160]
    After a period of 5 hours, gas chromatography-FID is carried out for determination. The conversion rate of compound A is 81%. It is observed that an increase in temperature would cause some increase in the reaction rate.
    [Comparative example 1]
    Step A of Example 2 is repeated on the same scale under the same conditions. Consequently, 260 g of the first distillation fraction (content of compound A = 350 ppm) are recovered. The total amount of this first distillation fraction is directly subjected again to distillation under ordinary pressure (the number of theoretical plates is adjusted to 10 and the reflux ratio is adjusted to 5 to 20 as in step A of the Example 2) without step la with the addition of 18 g of a 1% aqueous sodium hydrogen phosphate solution.
    [0162]
    However, the detection level of compound A does not decrease a level below the detection limit (1 ppm) under the above conditions. As a result, the main distillation traction is not recovered. In other words, it is observed that it is impossible to recover high purity sevoflurane by simply repeating the distillation of the first distillation fraction without step la.
    [Comparative example 2]
    Attempts are made to conduct a reaction as described above using the same reaction materials and the same reaction vessel by contacting compound A (5 g) and anhydrous HF (20 g) in contact with each other. the other without the addition of water (100 g) used as reaction material in Example 1 (step 1) above (with the use of 1,2-dichloroethane (DCE) (15 g) in as an internal standard substance).
    [0164]
    The peak area ratio of [compound A] / [DCE] is 0.57 immediately before the start of the reaction. However, as a result of determining the ratio
    BE2017 / 5207 peak area of [compound A] / [DCE] by gas chromatography-FID analysis 5 hours later, the peak area ratio of [compound A] / [DCE] remains practically unchanged (0.56). Therefore, it is believed that Compound A hardly reacts under anhydrous conditions.
    Industrial applicability [0165]
    The present invention is advantageous in that a compound A can be converted into compound X, which can be easily separated from sevoflurane (step 1).
    [0166]
    In addition, in another embodiment, the present invention is advantageous in that it is possible to allow the compound A in a 1st organic liquid to react selectively, so as to produce a 2nd organic liquid containing a reduced content of compound A or containing substantially no compound A (step la).
    [0167]
    In addition, in another additional embodiment, the present invention is advantageous in that it is possible to produce sevoflurane containing substantially no compound A in a significantly large amount compared to the case where step la n 'is not conducted, using, as a raw material, the 1st organic liquid which has been conventionally difficult to use effectively (step la and step 2).
    [0168]
    In addition, in another additional embodiment, the present invention is further advantageous in that it is unexpectedly possible to produce sevoflurane using, as a raw material, residues (bottom of the tank) remaining after distillation in step 2 (step la and steps 2 to 4).
    [0169]
    According to the present invention, it becomes possible to produce sevoflurane by using, as starting material, sevoflurane containing a compound A (1st organic liquid) which has been difficult to use effectively, so as to provide an improved production process. sevoflurane.
    BE2017 / 5207
    权利要求:
    Claims (13)
    [1]
    1. Method for reducing the amount of a compound A, comprising the following step:
    step 1 of bringing fluoromethyl ether, 1,3,3,3-pentafluoroisopropenyl (compound A) into contact with a composition containing hydrogen fluoride and water at a mass ratio of 1: 1 to 1:30.
    [2]
    2. Method for producing a second organic liquid, comprising the following step:
    step la of bringing a liquid (1st organic liquid) containing sevoflurane and fluoromethyl ether-l, l, 3,3,3-pentafluoroisopropenyl (compound A) into contact with a composition containing hydrogen fluoride and water at a mass ratio of 1: 1 to 1:30, so as to obtain the following liquid (i) or (ii) (2nd organic liquid): (i) an organic liquid containing sevoflurane and the compound A in an amount which is less than that in the 1st organic liquid; or (ii) an organic liquid containing sevoflurane and substantially no compound A.
    [3]
    3. The method of claim 2, wherein the temperature during contact is from 0 ° C to 60 ° C.
    [4]
    4. Method according to claim 2 or 3, wherein the contact is carried out in the presence of hexafluoroisopropyl alcohol (HFIP).
    [5]
    5. Method for producing sevoflurane containing substantially no compound A, comprising the following step:
    step 2 of distillation of the 2nd organic liquid obtained by the process according to any one of claims 2 to 4 in the presence of a degradation inhibitor, so as to obtain sevoflurane containing substantially no compound A as a distillation fraction main.
    [6]
    6. The method of claim 5, wherein the degradation inhibitor used in step 2 is at least one member selected from the group consisting of NaHCO 3 , Na 2 B 4 O 7 , H 3 BO 4 , C 6 H 4 (COOK) (COOH), Na 2 SO 3 , Na 2 HPO 4 , CH 3 COONa, and Na 3 PO 4 .
    BE2017 / 5207
    [7]
    7. The method of claim 5 or 6, further comprising the following step: step 3 of contacting anhydrous hydrogen fluoride and a reaction accelerator with the residues (3rd organic liquid) remaining after distillation in step 2, so as to obtain a liquid (4th organic liquid) in which at least part of a component in the 3rd organic liquid is converted into sevoflurane.
    [8]
    8. The method of claim 7, further comprising the following step: step 4 of distilling the 4th organic liquid so as to obtain sevoflurane containing substantially no compound A as the main distillation fraction.
    [9]
    9. Method according to any one of claims 2 to 8, in which the 1st organic liquid is obtained as the first distillation fraction in the following step:
    stage A of distillation of sevoflurane in the presence of a degradation inhibitor so as to collect the first fraction of distillation.
    [10]
    10. The method of claim 9, wherein the degradation inhibitor used in step A is at least one member selected from the group consisting of NaHCO 3 , Na 2 B 4 O 7 , H 3 BO 4 , C 6 H 4 (COOK) (COOH), Na 2 SO 3 , Na 2 HPO 4 , CH 3 COONa, and Na 3 PO 4 .
    [11]
    11. A method for producing sevoflurane containing substantially no compound A, comprising the following steps:
    step lb of contacting a liquid (1st organic liquid) containing sevoflurane and fhroromethyl ether-l, l, 3,3,3-pentafluoroisopropenyl (compound A) with a composition containing hydrogen fluoride ( HF) and water at a mass ratio of 1: 1 to 1:30 in the presence of hexafluoroisopropyl alcohol (HFIP) at 0 ° C to 60 ° C, so as to obtain the liquid (i) or (ii ) following (2nd organic liquid): (i) an organic liquid containing sevoflurane and compound A in an amount which is less than that in the 1st organic liquid; or (ii) an organic liquid containing sevoflurane and substantially no compound A; and step 2 of distillation of the 2nd organic liquid in the presence of a degradation inhibitor, so as to obtain sevoflurane containing substantially no compound A as the main distillation fraction.
    BE2017 / 5207
    [12]
    12. The method according to claim 11, further comprising the following steps:
    step 3 of contacting residues (3rd organic liquid) remaining after distillation in step 2 with anhydrous hydrogen fluoride and a reaction accelerator, so as to obtain a liquid (4th organic liquid) in which at at least part of the 3rd organic liquid is converted to sevoflurane; and step 4 of distilling the 4th organic liquid in the presence of a degradation inhibitor, so as to obtain sevoflurane containing substantially no compound A as the main distillation fraction.
    BE2017 / 5207
    SHORT
    PROCESS FOR PRODUCING SEVOFLURANE
    An object of the present invention is the removal of a compound A from sevoflurane containing fluoromethyl ether-1,3,3,3-pentafluoiOisopropenyl (compound A) so as to collect purity sevoflurane high. The present invention relates to a process for producing sevoflurane containing substantially no compound A, comprising the following steps of: bringing a
    10 composition containing hydrogen fluoride (HF) and water at a mass ratio of 1: 1 to 1:30 with a 1st organic liquid containing sevoflurane and a compound A, so as to obtain a 2nd organic liquid containing compound A in an amount which is less than that in the 1st organic liquid (step la); and distillation of the 2nd organic liquid in the presence of a degradation inhibitor, so as to obtain
    [13]
    Sevoflurane containing substantially no compound A as the main distillation fraction (step 2).
    Request number nati on aie
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0003147B1|1981-12-30|Process for separating hydrogen fluoride from its mixtures with 1-chloro-1,1-difluoroethane
    CA2245155C|2008-11-18|Process for separation of hydrogen fluoride from its mixtures with a hydrofluoroalkane containing 3 to 6 carbon atoms
    BE1024581B1|2018-04-11|PROCESS FOR PRODUCTION OF SEVOFLURAN
    FR3058721B1|2019-06-14|PROCESS FOR PRODUCING HEXAFLUOROISOPROPANOL AND FLUOROMETHYL HEXAFLUOROISOPROPYL ETHER |.
    EP0669303B1|1997-10-29|Process for the separation of hydrogen fluoride and difluoromethane
    EP2203405B1|2011-08-17|Method for recovering fluorocarboxylic acids
    EP0297947A1|1989-01-04|Process for the preparation of 1-chloro-1,1-difluoroethane
    EP0735023A1|1996-10-02|Reagent and process for the synthesis of organic sulphoxylated and fluorinated derivatives
    NL2018600B1|2017-09-26|Method for producing sevoflurane
    CA2050906C|1997-08-26|Process for preparing citral
    JP5668319B2|2015-02-12|Method for producing 2,2-bis | hexafluoropropane
    EP1165475B1|2004-01-14|Method for separating hydrogen fluoride from its mixtures with 1,1,1,3,3-pentafluorobutane and method for making 1,1,1,3,3-pentafluorobutane
    EP2763937B1|2018-01-31|Method of recycling hydrochloric and hydrofluoric acid effluent
    WO2022013440A1|2022-01-20|Method for synthesising 2-bromoglutaric acid diesters
    WO2018037999A1|2018-03-01|Method for converting butenes, and method for purifying monofluorobutane
    EP0195171B1|1989-03-29|Process for the preparation of monochlorohydroquinones
    WO2019165557A1|2019-09-06|Inhibitor for alkali and alkaline earth metals
    WO2020079281A1|2020-04-23|Adducts of triphenylphosphine and triphenylphosphite and their use for the bromination of primary alcohols
    EP0519808A1|1992-12-23|Process for the synthesis of a perfluoroalkyl bromide by photobromination of the corresponding iodide
    BE705513A|1968-04-23|
    FR2787443A1|2000-06-23|Separation of hydrogen fluoride from 1,1,1,3,3-pentafluorobutane comprises extraction with chloro- and/or fluorobutane derivatives
    FR2477532A1|1981-09-11|High selectivity continuous prepn. of glycerine di:chlorohydrin - from allyl chloride mixed with air, chlorine and water
    FR2743067A1|1997-07-04|New reagent, useful for the prepn. of fluorinated and oxo-sulphurated derivs.
    同族专利:
    公开号 | 公开日
    US10065912B2|2018-09-04|
    EP3323799A1|2018-05-23|
    JP2018127438A|2018-08-16|
    JP6299905B1|2018-03-28|
    US20180222834A1|2018-08-09|
    FR3062651A1|2018-08-10|
    RU2666536C1|2018-09-11|
    FR3062651B1|2019-07-26|
    EP3323799B1|2019-04-24|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4328376A|1980-03-31|1982-05-04|Baxter Travenol Laboratories, Inc.|Method of removing fluorinated olefin byproduct formed during the synthesis of a fluorinated ether|
    EP0701985A1|1994-03-31|1996-03-20|Central Glass Company, Limited|Method of purifying fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether|
    EP0822172A1|1996-02-21|1998-02-04|Central Glass Company, Limited|Process for preparing fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether|
    WO1999044978A1|1998-03-03|1999-09-10|Central Glass Company, Limited|Process for purifying fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether|
    US4250334A|1979-12-26|1981-02-10|Baxter Travenol Laboratories, Inc.|Method of synthesizing fluoromethylhexafluoroisopropyl ether|
    JP2786106B2|1994-03-28|1998-08-13|セントラル硝子株式会社|Method for purifying fluoromethyl-1,1,1,3,3,3-hexafluoroisopropyl ether|
    JP2865554B2|1994-04-08|1999-03-08|セントラル硝子株式会社|Gas chromatographic analysis of fluoromethyl-1,1,1,3,3,3-hexafluoroisopropyl ether|
    JP3240043B2|1996-01-23|2001-12-17|セントラル硝子株式会社|Purification method of fluoromethyl-1,1,1,3,3,3-hexafluoroisopropyl ether|
    GB0031303D0|2000-12-21|2001-01-31|Ici Plc|Process for the purification of fluoromethyl hexafluoroisopropyl ether|
    WO2005068997A1|2004-01-05|2005-07-28|Halocarbon Products Corporation|Chromatographic method for the analysis of both in process and finished sevoflurane|
    PL383328A1|2004-11-17|2008-02-18|Minrad Inc.|Sevoflurane production method|
    KR100997836B1|2005-08-04|2010-12-01|할로카본 프로덕츠 코포레이션|Purification of fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether sevoflurane|
    US7732647B2|2007-12-27|2010-06-08|Halocarbon Products Corporation|Process for the purification of fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether |
    JP5434236B2|2009-04-28|2014-03-05|セントラル硝子株式会社|Method for producing fluoromethylhexafluoroisopropyl ether|
    US8729313B2|2011-08-15|2014-05-20|Baxter International Inc.|Process for the manufacturing of sevoflurane|
    JP6237862B1|2016-11-16|2017-11-29|セントラル硝子株式会社|Method for producing hexafluoroisopropanol and fluoromethyl hexafluoroisopropyl ether |
    法律状态:
    2018-05-03| FG| Patent granted|Effective date: 20180411 |
    优先权:
    申请号 | 申请日 | 专利标题
    JP2017019555|2017-02-06|
    JP2017019555|2017-02-06|
    JP2017044726A|JP6299905B1|2017-02-06|2017-03-09|Method for producing sevoflurane|
    [返回顶部]